Here are three things to know.
1. Ixifi is a biosimilar version of Johnson & Johnson’s immunosuppressive drug Remicade.
2. The drug is intended to treat rheumatoid arthritis, Crohn’s disease and plaque psoriasis, among other illnesses.
3. Both Ixifi and Remicade contain a boxed warning over an increased risk of serious infections and cancer.
More articles on supply chain:
Eli Lilly forecasts $23B in revenue for 2018
Investor group pushes big pharma to report links between pricing and executive compensation
FDA to add alternative approval pathway for medical devices: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
